Luo Qi, Li Jinsui, Su Xiaohan, Tan Qiao, Zhou Fangfang, Xie Shaoli
Department of Academician (expert) Workstation, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.
Biological Targeting Laboratory of Breast Cancer, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.
Front Genet. 2022 Sep 9;13:935860. doi: 10.3389/fgene.2022.935860. eCollection 2022.
Breast cancer is the malignant tumor with the highest incidence rate at present, and its incidence rate ranks first in the female population. COL11A1 is an important component of collagen XI and is considered to play an important role in a variety of connective tissue diseases. Recent studies have shown that COL11A1 is associated with the occurrence and development of many kinds of malignant tumors. However, its prognostic value in breast cancer and its correlation with immune cell infiltration in tumor tissue are not clear. In this paper, we reveal the prognostic value of COL11A1 in breast cancer and its tumor immune-related function through in-depth bioinformatics analysis. The expression of COL11A1 is abnormally upregulated in breast cancer and is significantly related to the poor prognosis of breast cancer. In the analysis of the clinical characteristics of the patients, we found that the expression level of COLL11A1 was closely related to lymph node metastasis, PAM50 (Prediction Analysis of Microarray 50) expression, clinical stage and so on. Gene Ontology (GO) and Kyoto Encyclopedia of Gene and Genome (KEGG) all suggest that COL11A1 is related to tumor immunity. Further study found that the COL11A1 expression was significantly correlated with the degree of immune infiltration and the expression of a variety of immune cell markers in tumor tissue. More importantly, COL11A1 can affect the prognosis of breast cancer patients by participating in the regulation of tumor immune infiltration. Therefore, we believe that COL11A1 is a very potential target for diagnosis and treatment of breast cancer.
乳腺癌是目前发病率最高的恶性肿瘤，其发病率在女性群体中位居首位。COL11A1是Ⅺ型胶原的重要组成部分，被认为在多种结缔组织疾病中发挥重要作用。最近的研究表明，COL11A1与多种恶性肿瘤的发生发展相关。然而，其在乳腺癌中的预后价值以及与肿瘤组织中免疫细胞浸润的相关性尚不清楚。在本文中，我们通过深入的生物信息学分析揭示了COL11A1在乳腺癌中的预后价值及其肿瘤免疫相关功能。COL11A1在乳腺癌中的表达异常上调，且与乳腺癌的不良预后显著相关。在对患者临床特征的分析中，我们发现COL11A1的表达水平与淋巴结转移、PAM50（微阵列50预测分析）表达、临床分期等密切相关。基因本体论（GO）和京都基因与基因组百科全书（KEGG）均提示COL11A1与肿瘤免疫相关。进一步研究发现，COL11A1表达与肿瘤组织中免疫浸润程度及多种免疫细胞标志物的表达显著相关。更重要的是，COL11A1可通过参与肿瘤免疫浸润的调控影响乳腺癌患者的预后。因此，我们认为COL11A1是乳腺癌诊断和治疗的一个极具潜力的靶点。
